Having trouble accessing articles? Reset your cache.

Boehringer's afatinib misses lung cancer endpoint

Boehringer Ingelheim GmbH (Ingelheim, Germany) said afatinib plus best supportive care (BSC) missed the primary endpoint

Read the full 169 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE